These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1549093)

  • 1. [Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report].
    Shiba E; Kobayashi T; Yayoi E; Takatsuka Y; Koyama H; Takai S; Mori T
    Nihon Geka Gakkai Zasshi; 1992 Jan; 93(1):109. PubMed ID: 1549093
    [No Abstract]   [Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
    Reilly D; Andreasen P; Duffy MJ
    Biochem Soc Trans; 1991 Feb; 19(1):44S. PubMed ID: 1903741
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasminogen activator activity and composition in human breast cancer.
    Evers JL; Patel J; Madeja JM; Schneider SL; Hobika GH; Camiolo SM; Markus G
    Cancer Res; 1982 Jan; 42(1):219-26. PubMed ID: 7198508
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Jänicke F; Schmitt M; Graeff H
    Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue.
    Virtanen OJ; Sirén V; Multanen J; Färkkilä M; Leivo I; Vaheri A; Koskiniemi M
    Eur J Oral Sci; 2006 Feb; 114(1):22-6. PubMed ID: 16460337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The immunoenzyme determination of plasminogen activators and their inhibitor in breast tumors: the connection to clinico-morphological prognostic factors].
    Gershteĭn ES; Mamedov UR; Kostyleva OI; Kushlinskiĭ NE
    Klin Lab Diagn; 2000 Mar; (3):16-21. PubMed ID: 10878926
    [No Abstract]   [Full Text] [Related]  

  • 8. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of exogenous growth factors on the expression of plasminogen activators and plasminogen activator inhibitors by cells isolated from normal and healing rabbit ligaments.
    Murphy PG; Hart DA
    J Orthop Res; 1994 Jul; 12(4):564-75. PubMed ID: 7520487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of the enzyme activity of the fibrinolytic system using fibrinogen conjugated with peroxidase].
    Liaginskiĭ AV; AfanasenkoGA ; Gudkova EV
    Lab Delo; 1991; (11):27-31. PubMed ID: 1722843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zymographic evaluation of plasminogen activators and plasminogen activator inhibitors.
    Ramsby ML
    Adv Clin Chem; 2004; 38():111-33. PubMed ID: 15521190
    [No Abstract]   [Full Text] [Related]  

  • 13. [The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis].
    Bumblite ID; Poliantseva LR; Mukhin NA; Andreenko GV; Podorol'skaia LV; Liaginskiĭ AV; Varlamova NV
    Ter Arkh; 1992; 64(11):52-6. PubMed ID: 1293845
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasminogen activator in human breast cancer cytosols: revisited after five years.
    Ng R; Sutherland DJ; Szalai JP; Kellen JA
    In Vivo; 1991; 5(4):313-6. PubMed ID: 1810415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
    Verspaget HW; Sier CF; Ganesh S; Griffioen G; Lamers CB
    Eur J Cancer; 1995; 31A(7-8):1105-9. PubMed ID: 7577001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic components in fetal membranes and amniotic fluid.
    Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
    Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
    Sirén V; Peltonen J; Vaheri A
    Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy.
    Rahr HB; Sørensen JV; Larsen JF; Jensen FS; Bredahl C
    Scand J Gastroenterol; 1996 Feb; 31(2):170-4. PubMed ID: 8658040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Distribution of plasminogen activator and its inhibitor in the vascular bed].
    Bratchik AM; Gribkov SA
    Vrach Delo; 1987 Jan; (1):66-9. PubMed ID: 3105177
    [No Abstract]   [Full Text] [Related]  

  • 20. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.